1989), and HER-2/neu oncogene (Hetzel et al, 1992) have been extensively studied in the past years.
Tumour invasion and metastasis are complex processes in which proteases that promote the breakdown of basement membrane and extracellular matrix play a central role, cathepsin D (Cat D) being one of the most studied. Cat D is an acidic aspartil lysosomal endopeptidase produced as a 52-kDa precursor, which is then processed to a 48-kDa intermediate, and then to a 34-kDa mature stable form (Caponi et al, 1986) . In human breast cancer cells, altered normal sorting and maturation resulted in a marked increase in Cat D secretion (Caponi et al, 1989) . Besides its enzymatic activity, Cat D is a mitogen, acting through its binding to the insulin-like growth factor type II receptor (Mathieu et al, 1990) . Cat D expression is controlled by oestrogen and growth factors in human breast cancer cells (Westley et al, 1980; Rochefort et al, 1990) . However, in both human endometrial cancer cell lines (Touitou et al, 1989) , rat uterus (Elangovan et al, 1980) , and normal human endometrium (Maudelonde et al, 1990) , Cat D expression is under regulation by progesterone and growth factors, but not by oestrogen.
The usefulness of Cat D as a prognostic factor has been extensively studied in breast cancer in which high levels of the protease have been associated with a worse prognosis either in whole tumour series or in node-negative or node-positive patients (Spyratos et al, 1989; Thorpe et al, 1989; Tandon et al, 1990; Foekens et al, 1993; Ferrandina et al, 1997) , although discrepant findings have also been reported (Ravdin et al, 1994 (Ravdin et al, , 1997 . In contrast, there are few data on Cat D in endometrial cancer, and only one report deals with its prognostic value (Lšsch et al, 1996) .
In the present study, we examined the relationship between Cat D and established clinicopathological prognostic parameters and biological predictors in a series of 156 patients with primary endometrial cancer. The prognostic value of Cat D was also studied in a subset of 97 patients followed for at least 2 years or until death. Our results suggest that a low tumoral Cat D content is predictive of persistent or recurrent disease.
MATERIALS AND METHODS

Patients
This study was performed on 156 consecutive patients diagnosed with surgical stage IÐIII primary endometrial cancer between June 1990 and June 1997, and treated at the Department of Obstetrics and Gynaecology at the Hospital Materno Infantil in Las Palmas (Canary Islands, Spain). None of the patients had received substitutive hormonal therapy for at least 3 months before diagnosis. All patients underwent exploratory laparotomy, total hysterectomy and bilateral salpingo-oophorectomy. Radiation therapy after surgery was administered to all patients in stages II and III, and to patients in stage I with risk factors such as serous and clear cell histological types, deep myometrial invasion, and high histological grade. The treatment consisted of irradiation of either the vaginal cuff (45Ð60 Gy) (n = 8), the whole pelvis (50 Gy) (n = 5), or both (n = 62). Additionally, two patients received irradiation in the whole pelvis and in the para-aortic nodes (45 Gy). Complete clinical information was obtained for all patients. This included age at diagnosis, menopausal status, histological type, histological grade, depth of myometrial invasion, surgical stage according to the International Federation of Gynaecology and Obstetrics (FIGO) classification, vascular invasion, and presence of metastatic disease. Information on peritoneal affection was available in 126 patients, but that on lymph node involvement was very limited because lymphadenectomy was performed in only 16 cases.
Tissue fractionation
Tumour specimens were promptly frozen in liquid nitrogen after surgery and then kept at Ð70°C until assay. The percentage of tumoral tissue (cancer cell plus stroma) present in each specimen was almost 100% in most cases (selected under macroscopic inspection by the pathologist). Samples (100Ð200 mg) were homogenized in ten volumes of buffer containing 10 mM tris-HCl, pH 7.4, 1.5 mM disodium EDTA, 10 mM sodium molybdate, 0.1% monothioglycerol, 1 mM phenylmethylsulphonyl fluoride, 1 µg ml Ð1 aprotinin, 1 mM sodium orthovanadate and 10% glycerol. Aliquots of homogenates were used to measure the total cellular p185 HER-2/neu (p185) content. The rest of the homogenates were centrifuged at 1000 g for 15 min at 4°C, and the supernatants were centrifuged again at 105 000 g for 1 h at 4°C to obtain the cytosols. 
Assays
Cat D was measured in the cytosol using a solid phase two-site radiometric immunoassay (Elsa-Cath-D; Cis biointernational, Gifsur-Yvette, France). Briefly, cytosols were diluted to a protein concentration of 1 mg ml Ð1 and the assay was performed in duplicate after a further 81-fold dilution. The best cut-off level to consider that a given specimen contained a high content of Cat D was 40 pmol mg Ð1 protein (see below). For the measurement of ER and PR, cytosols were diluted to 1 mg protein ml Ð1 with 0.1% bovine serum albumin (BSA) and were incubated overnight in duplicate at 0Ð4°C with either 5 nM of [ 3 H]-oestradiol or 10 nM of [ 3 H]R5020 (NEN, Boston, MA, USA), in the presence or absence of a 200-fold excess of unlabelled diethylstilboestrol or R5020, respectively, to correct for nonspecific binding. At the end of the incubation period, the unbound steroid was removed by dextran-coated charcoal treatment (0.05% dextran T-70, 0.5% activated charcoal). Tumours were classified as ER or PR positive if the content of ER and PR was equal to or greater than 10 and 30 fmol mg Ð1 protein respectively.
The total cellular p185 content was measured in the homogenates from tumour samples by a commercial enzymelinked immunosorbent assay (ELISA) (human neu-oncoprotein ELISA; Oncogene Science, Uniondale, NY, USA). Aliquots of 50 µl of the tissue homogenates were incubated for 5 min at room temperature with 10 µl of antigen-extraction agent and centrifuged at 14 000 g for 10 min at 4°C. The protein concentration of supernatant was diluted to 10 µg ml Ð1 , or further if necessary, and the assay was performed in duplicate according to the instructions given by the manufacturer. A level of p185 equal to or higher than 260 fmol mg Ð1 protein, previously validated by us in breast cancer (Valer-n et al, 1996) , was used to consider that a given tumour overexpressed the oncoprotein.
The protein concentration was estimated by the Bradford method (Bio-Rad, Richmond, CA, USA) using BSA as a standard.
For flow cytometry analysis, fine-needle aspiration of tissue samples was used for initial mechanical disaggregation. The aspirates were flushed with buffer containing 3.4 mM trisodium citrate, pH 7.6, 0.1% Nonidet P-40, 1.5 mM spermine tetrahydrochloride and 0.5 mM Tris. The suspensions were then clarified by filtering through a 50-µm nylon mesh and centrifuged at 200 g for 5 min. Pellets were resuspended in 100 µl of buffer and treated according to the method of Vindelov and Christensen (1990) . Stained nuclei were analysed on an EPICS XL-MCL cytometer (Coulter Corporation, Hialeah, FL, USA). Quality control of the flow cytometer was carried out using DNA-Check Epics Alignment Fluorospheres (Coulter). Peak integrated red fluorescence, gated along the diagonal, was used to analyse 20 000 nuclei, and data were stored in list mode. Half-peak coefficients of variation were always lower than 5%. Generated histograms were analysed for cell cycle compartments and background debris subtraction using the Multicycle software for cell cycle analysis (Phoenix Flow Systems, San Diego, CA, USA). In accordance with previous studies (Lukes et al, 1994) , tumours with a DNA index equal to or greater than 1.25 were considered aneuploid. The best cut-off point to discriminate between high and low S-phase was 11% (see below).
Follow-up
All patients were routinely examined every 3 months for the first 2 years and then every 6 months. A subset of 97 patients, who were followed for at least 2 years or until death, was selected to study the prognostic value of the variables analysed. Time to event was defined as the period of time from diagnosis to either the date of recurrence for patients with a disease-free interval after surgery or the date of surgery for patients who never became free of disease. For the whole subset, the median follow-up time was 42 months (range 0.2Ð91 months). There were 22 patients with either recurrent (n = 17) or persistent (n = 5) disease. Their median follow-up time was 14 months (range 0.2Ð83 months). Among these patients, 15 (68.2%) died of endometrial cancer, including five out of five (100%) patients with persistent disease and 10 out of 17 (58.8%) patients with recurrent disease. The remaining 75 patients without recurrent or persistent disease were alive at the last follow-up. The median follow-up time of these patients was 49 months (range 24Ð91 months).
Statistical analysis
Correlations between Cat D and steroid receptors, p185 and Sphase were performed by SpearmanÕs rank correlation coefficient. The non-parametric MannÐWhitney or KruskalÐWallis tests were used for comparison between the medians of two or more groups respectively. The relationship between Cat D status and that of other prognostic variables was examined in contingency tables using the chi-squared or FisherÕs exact tests. Cat D and S-phase were dichotomized using the minimum P-value method by selecting the best cut-off value that allowed the maximal separation between groups at low and high risk for persistence or relapse. To confirm the statistical significance of the selected value, the levels of the studied variables were logarithmically transformed 
RESULTS
Characteristics of the tumours
The characteristics of our tumour series are listed in Table 1 . The mean and median age of the patients was 65 years (range 29Ð93 years). Most of the patients were post-menopausal (93.6%), and the predominant histological type was endometrioid (89.1%). Among the 17 tumours of non-endometrioid histological type, five were serous and 12 clear cell. Half of the tumours were well differentiated (51.3%) and two-thirds were confined to the endometrium or invaded less than half of the myometrium. Surgical stage I was predominant (73.1%), vascular space involvement existed in 22.4% of the patients, and 8.7% of cases had a positive peritoneal cytology. The Cat D content of the tumours followed a gaussian distribution when the values were logarithmically transformed (Figure 1 ). According to the selected cut-off point, 38.5% of tumours had a low Cat D level, whereas 61.5% had a high content. The descriptive statistic of all quantitatively analysed variables is shown in Table 2 . The number of positive specimens for ER and PR was 82.1% and 84% respectively. The p185 content was elevated in 17.9% of cases, and 17.9% of tumours had a high S-phase. Furthermore, 16% of tumours were aneuploid, considering a DNA index of 1.25 as the cut-off point.
Relationship between Cat D content and clinicopathological or biological parameters
Table 1 also shows the relationship between Cat D levels and the clinicopathological characteristics of patients. There was no association between the tumoral Cat D content, considered either as continuous or categorical variable, and any of the established prognostic parameters.
Spearman correlation analyses between Cat D and steroid receptors, p185 and S-phase showed that Cat D did not correlate to any of the quantitatively analysed variables, with the exception of a weak positive correlation with p185 (r = 0.2; P = 0.01). Similarly, there was no association between Cat D content, considered either as a continuous or categorical variable, and the rest of the biological variables analysed (Table 3) .
Survival analysis
Results of the univariable survival analysis are shown in Table 4 . Age at diagnosis, high histological grade, advanced surgical stage, Cut-off levels for biological variables as in Table 3 .
low levels of Cat D, negative ER and PR status, aneuploidy, high S-phase, vascular invasion and positive peritoneal cytology were positively associated with persistent or recurrent disease. The multivariate survival analysis (Table 5) , performed without considering peritoneal cytology because of the small number of patients in which it was estimated (n = 73), showed that histological grade, surgical stage, Cat D and PR were significantly associated with disease-free survival. Among them, Cat D had one of the higher risk ratios; thus, in a given patient with a low Cat D content, the hazard risk of persistent or recurrent disease was 2.19-fold higher than in those patients with a Cat D level above the cut-off point. The Kaplan and Meier curve for Cat D is depicted in Figure 2 . Although 39% of patients with low Cat D levels had persistent or recurrent disease at the last follow-up, this circumstance existed in only 10.7% of those patients with a Cat D content above the cut-off point (P = 0.0015).
To discard the possibility that the treatment modality biased these results, a separate analysis was performed for patients treated with surgery alone, or with surgery and radiotherapy. In each subgroup, patients with a low Cat D content had a significantly worse outcome than patients with high Cat D (Table 6 ).
DISCUSSION
The literature contains very little information about the role of Cat D in endometrial cancer. To date, only six articles deal with Cat D expression in this tumour type, and its prognostic significance has only been studied in one of them. These studies were performed on relatively small series, because only one group included more than 100 cases (Lšsch et al, 1996) . In one study, Cat D levels were quantified by ELISA (Maudelonde et al, 1990) , and in three (Nazeer et al, 1992; Scambia et al, 1995; Sanfilippo et al, 1996) by an immunoradiometric (IRMA) procedure similar to that used by us. In another article, Cat D was detected by immunohistochemistry (IHC) (Lšsch et al, 1996) . The two procedures (IRMA and IHC) were compared in one article (Nazeer et al, 1994 ) using a patient series very similar to one in which Cat D concentration was determined by IRMA by the same group (Nazeer et al, 1992) . It has been suggested that the tumoral cytosolic Cat D values obtained by the immunoradiometric assay used in this work may be impaired by the relative contribution of non-tumoral cells (Isola et al, 1993) , which makes the IHC method more specific. However, some authors have reported that total cytosolic Cat D correlates well with Cat D content in cancer cells (Roger et al, 1994) , and that Cat D levels in cancer and stromal cells are directly correlated (Ravdin et al, 1994) . In addition, the assessment of Cat D content by the immunoradiometric assay seems likely to give reliable and comparable interstudy results as assessed by the EORTC Receptor Study Group (Benraad et al, 1992) .
Our results showed that Cat D is expressed in variable amounts in endometrial cancer, its levels being slightly lower than or similar to those reported by some authors in breast cancer (Foekens et al, 1993; Marsigliante et al, 1994; Gion et al, 1995; Valer-n et al, 1997) . Our data in endometrial cancer are similar to those published by Sanfilippo et al (1996) and higher than those reported by three other groups (Maudelonde et al, 1990; Nazeer et al, 1992; Scambia et al, 1995) . The reasons underlying these divergent results are not clear because most of these authors used essentially the same methodology as that used by us.
We did not find an association between Cat D levels and those of the established clinicopathological prognostic factors, which Table 3 . agrees with data reported by Lšsch et al (1996) , and contrasts with other reports in which Cat D content was positively associated with histological type (Nazeer et al, 1992) , myometrial invasion (Maudelonde et al, 1990; Nazeer et al, 1992) , and grade of differentiation (Nazeer et al, 1992) . Conversely, Scambia et al (1995) reported an inverse association between Cat D and myometrial invasion and stage. One possible explanation for these discrepancies could rely on the relatively small series which most of the cited studies used.
There is evidence that Cat D gene expression is increased by progesterone, but not by oestrogen, both in rat uterus (Elangovan et al, 1980) and in normal human endometrium (Maudelonde et al, 1990 ). We did not find any correlation or association between Cat D and steroid hormone receptors, either in the whole tumour series or in the subgroup of PR-positive tumours (data not shown). These results are in accordance with two previous reports (Maudelonde et al, 1990; Nazeer et al, 1992 ) and disagree with another in which a positive association between Cat D and ER/PR status was found (Scambia et al, 1995) . Our data suggest that in endometrial cancer the hormone dependence of Cat D expression is lost or, alternatively, the role that growth factors play in its regulation are more important than that exerted by sex hormones.
There are no data in the literature regarding the relationship between Cat D and p185, ploidy and S-phase in endometrial cancer. We could not find any correlation or association between Cat D and ploidy and S-phase. Regarding p185, we observed a weak, although significant, positive correlation between these two variables, a finding that has also been described in breast cancer (Seshadri et al, 1994; Valer-n et al, 1997) .
To establish the prognostic value of a set of variables, a large series of patients followed for a long time is desirable. Our series did not completely fulfil these criteria, and for this reason we selected a subset of patients followed for at least 2 years or until death. Because the follow-up period was relatively short (median 46 months), we used survival analysis for persistent or recurrent disease, a clinical condition which is difficult to cure, instead of overall survival, which would require a more prolonged follow-up.
As expected, univariate survival analysis confirmed the prognostic value of known clinicopathological prognostic factors, including age at diagnosis, histological type, histological grade, surgical stage, vascular invasion and peritoneal cytology, which is in accordance with previous reports (Christopherson et al, 1983; Creasman et al, 1987; Morrow et al, 1991; Barakat et al, 1997) . However, histological type and depth of myometrial invasion lacked significance. This analysis also showed the prognostic significance of Cat D, ER, PR, ploidy and S-phase, but not that of p185. Multivariate analysis led us to determine the significance of biological factors in relation to conventional clinicopathological prognostic parameters. Our results showed that a high grade of differentiation, advanced surgical stage, low levels of cathepsin D and PR negativity are predictive of poor outcome. Therefore, and contrary to what might be expected, Cat D seems to be a favourable prognostic factor in endometrial cancer. This finding contrasts with that reported by Lšsch et al (1996) using immunohistochemistry to detect the protease. However, Scambia et al (1995) reported that high Cat D levels might be a good prognostic factor in endometrial cancer, although they could not obtain reliable survival analysis. As far as we know, this is the first time in which such an association has been described in endometrial cancer, although before us Henry et al (1990) found similar results in breast cancer. One could argue that high Cat D content reflects the functional integrity of the steroid hormone receptor pathway (Henry et al, 1990) , and that high levels of Cat D, as well as PRpositivity, are predictive of good prognosis. However, in our study, we did not find any relationship between Cat D and these receptors. It may also be possible that the acidic conditions needed for the Cat D to be active (Morisset et al, 1986) do not arise in endometrial cancer, but this does not explain the favourable incidence on prognosis of low Cat D levels. The question, then, is open to future research.
